The weekly litigation news digest is live. Subscribe now

IP Verse

Modulators Of Cystic Fibrosis Transmembrane Conductance Regulator - EP3798214

The patent EP3798214 was granted to Vertex Pharmaceuticals Incorporated on Sep 14, 2022. The application was filed on Oct 6, 2015 under application number EP20188642A. The patent is currently recorded with a legal status of "Granted And Under Opposition".

EP3798214

VERTEX PHARMACEUTICALS INCORPORATED
Application Number
EP20188642A
Filing Date
Oct 6, 2015
Status
Granted And Under Opposition
Aug 12, 2022
Publication Date
Sep 14, 2022
External Links
Slate, Register, Google Patents

Patent Summary

Compounds for treating cystic fibrosis (CF) by modulating CFTR chloride channel function. The compounds are CFTR potentiators that increase CFTR activity and anion transport. They can be used alone or in combination with other CFTR modulators to enhance CFTR function. The compounds have structures containing a 6-substituted 3-methylpyridine ring linked to a benzamide or benzoic acid moiety. They can be used as pharmaceuticals to treat CF by improving CFTR function in patients with CFTR mutations.

Patent Family

Patent Family

Patent Oppositions

Patent oppositions filed by competitors challenge the validity of a granted patent. These oppositions are typically based on claims of prior art, lack of novelty, or non-obviousness. They are a key part of the process for determining a patent's strength and enforceability.

CompanyOpposition DateRepresentativeOpposition Status
GENERICS UKJun 12, 2023ELKINGTON AND FIFEADMISSIBLE

Patent Citations (2) New

Patent citations refer to prior patents cited during different phases such as opposition or international search.

Citation PhasePublication Number
OPPOSITIONWO2010123822
SEARCHWO2010123822

Dossier Documents

The dossier documents provide a comprehensive record of the patent's prosecution history - including filings, correspondence, and decisions made by patent offices - and are crucial for understanding the patent's legal journey and any challenges it may have faced during examination.

  • Date

    Description

  • Get instant alerts for new documents